Evidence map›Paper›PMID 37218065›Full record

ArticleBritish journal of haematology2023

Long-term follow-up confirms the favourable prognostic impact of high numbers of tumour infiltrating CD3 T-cells in follicular lymphoma patients treated by rituximab-maintenance regimen.

Camille Laurent, Maria Flores, Loïc Chartier, Sarah Huet, Christopher R Bolen, Jeffrey M Venstrom, Catherine Chassagne-Clément, Peggy Dartigues-Cuilléres, Fréderic Charlotte, Bruno Tesson and 3 more

Open access · bronzeAbstract readLetter
In one paragraph

Article in British journal of haematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 2 countries.

Camille LaurentInstitut Universitaire Cancer-Oncopole, CHU Toulouse, INSERM U1037, Toulouse, France.ORCID 0000-0002-5375-7512
Maria FloresLYSARC, Pierre Bénite, France.
Loïc ChartierLYSARC, Pierre Bénite, France.
Sarah HuetHospices Civils De Lyon, Pierre Bénite, France.
Christopher R BolenGenentech Inc., South San Francisco, California, USA.
Jeffrey M VenstromGenentech Inc., South San Francisco, California, USA.
Catherine Chassagne-ClémentCentre Léon Bérard, Lyon, France.
Peggy Dartigues-CuilléresInstitut Gustave Roussy, Villejuif, France.
Fréderic CharlotteCentre Hospitalier Pitié-Salpêtriére, Paris, France.
Bruno TessonLYSARC, Pierre Bénite, France.
Gilles SallesMemorial Sloan Kettering Cancer Center, New York, New York, USA.
Franck MorschhauserHôpital Claude Huriez, Lille, France.
Luc XerriInstitut Paoli-Calmettes, CRCM and Aix-Marseille University, Marseille, France.
The Lymphoma Academic Research Organisation · FRAix-Marseille Université · FRCentre Léon Bérard · FRHôpital Claude Huriez · FRHospices Civils de Lyon · FRInserm · FRInstitut Gustave Roussy · FRMemorial Sloan Kettering Cancer Center · USSorbonne Université · FR

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Lymphoma, FollicularAntineoplastic Combined Chemotherapy ProtocolsFollow-Up StudiesHumansPrognosisRituximabT-LymphocytesRituximab

Identifiers

PMID37218065
PMCPMC10755216
OpenAlexW4377564384

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.